Table 1

Baseline characteristics

All patients
n=79
GIC>10 mL
n=30
No GIC
n=49
p Value
Sex (female/male)50/2916/1430/190.286
Age (years), mean±SD68±1371±1267±130.196
Hypertension (%)66.2%63%65%0.580
Diabetes mellitus (%)16.7%13%16%0.462
Atrial fibrillation (%)30.8%26%24%0.215
Hyperlipidemia (%)41%43%38%0.419
Admission glycemia (mg/dL), mean±SD126.9±45117±27132±540.199
NIHSS admission, median (IQR)17 (11–20)16 (11–21)14 (8–20)0.451
NIHSS 24 hours, median (IQR)11 (3–19)9 (2–16)12 (4–20)0.084
NIHSS improvement at 24 hours, median (IQR)3 (0–9)7 (1–14)2 (0–5)0.005
Clinical improvement (%)48.1%66.6%39%0.017
CT ASPECTS admission, median (IQR)9 (8–10)9 (8–10)10 (8–10)0.549
IV tPA pretreatment (%)58.2%56.6%54.2%0.508
Occlusion location0.611
 MCA-M1 (%)35 (44.3%)16 (53.3%)20 (40.8%)
 MCA-M2 (%)16 (20.2%)5 (16.6%)11 (22.4%)
 Terminal ICA (%)21 (26.5%)6 (20%)14 (28.5%)
 Tandem ICA/MCA (%)7 (8.8%)3 (10%)4 (8%)
TOAST0.294
 Atherothrombotic (%)14 (17.7%)2 (6%)12 (24.4%)
 Cardioembolic (%)45 (56.9%)20 (66.6%)23 (46.9%)
 Undetermined (%)13 (16.4%)4 (13.3%)9 (18.3%)
 Other determined (dissections)7 (8%)4 (13.3%)3 (6%)
  • ASPECTS, Alberta Stroke Program Early CT Score; GIC, ghost infarct core; ICA, internal carotid artery; IV tPA, IV tissue-type plasminogen activator; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; TOAST, trial of ORG 10172 in acute stroke treatment.